I-ting Liu

No. 138, Sheng Li Road, 
Tainan, TNQ, TW 
No. 138, Sheng Li Road, 
Tainan, TNQ, TW 

Overview

I-ting Liu practices practicing medicine in Tainan, Taiwan.

Their clinical expertise encompasses Shingles, Developmental Dysphasia Familial, Paroxysmal Cold Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), and Hepatectomy.

They are actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 3 clinical trials.

Locations

No. 138, Sheng Li Road, Tainan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab Paclitaxel, S1, Leucovorin, Oxaliplatin
Study Phase: Phase 2
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Not Applicable
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II Study
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study): a Single-arm, Phase II Study
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: BI-754091, Afatinib
Study Phase: Phase 2
View 2 Less Clinical Trials

25 Total Publications

Gut microbiota profiles across intrinsic capacity strata in community-dwelling older adults using full-length 16S rRNA sequencing.
Gut microbiota profiles across intrinsic capacity strata in community-dwelling older adults using full-length 16S rRNA sequencing.
Journal: GeroScience
Published: March 30, 2026

Frequently Asked Questions about I-ting Liu

Is I-ting Liu a top-rated expert for Shingles?

MediFind is an objective health platform that identifies experts based on real-world data. I-ting Liu is classified as an Experienced expert for Shingles, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does I-ting Liu participate in research or clinical trials?

Yes. I-ting Liu has published 25 articles and abstracts on conditions like Shingles. You can view a list of I-ting Liu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile